126 related articles for article (PubMed ID: 36857775)
1. High-Throughput Peptide Arrays Identify Potential Diagnostic Autoantibody Signatures in Early-Stage Lung Adenocarcinoma.
Luo R; Zhong P; Li X; Cai J; Tao Y; Xiong B; Zheng H; Zhang Z; Tang L; Yao J; Li Y; Shi Y; Han X
Cancer Epidemiol Biomarkers Prev; 2023 May; 32(5):726-738. PubMed ID: 36857775
[TBL] [Abstract][Full Text] [Related]
2. A Diagnostic Model With IgM Autoantibodies and Carcinoembryonic Antigen for Early Detection of Lung Adenocarcinoma.
Zhang X; Li J; Wang Y; Liu M; Liu F; Zhang X; Pei L; Wang T; Jiang D; Wang X; Zhang J; Dai L
Front Immunol; 2021; 12():728853. PubMed ID: 35140701
[TBL] [Abstract][Full Text] [Related]
3. Plasma extracellular vesicle microRNA profiling and the identification of a diagnostic signature for stage I lung adenocarcinoma.
Gao S; Guo W; Liu T; Liang N; Ma Q; Gao Y; Tan F; Xue Q; He J
Cancer Sci; 2022 Feb; 113(2):648-659. PubMed ID: 34837453
[TBL] [Abstract][Full Text] [Related]
4. Molecular fingerprints of nuclear genome and mitochondrial genome for early diagnosis of lung adenocarcinoma.
Xu Y; Yang Y; Wang Y; Su J; Chan T; Zhou J; Gong Y; Wang K; Gu Y; Zhang C; Wu G; Bi L; Qin X; Han J
J Transl Med; 2023 Apr; 21(1):250. PubMed ID: 37038181
[TBL] [Abstract][Full Text] [Related]
5. Development and validation of a robust immune-related prognostic signature in early-stage lung adenocarcinoma.
Wu P; Zheng Y; Wang Y; Wang Y; Liang N
J Transl Med; 2020 Oct; 18(1):380. PubMed ID: 33028329
[TBL] [Abstract][Full Text] [Related]
6. Gut mycobiome as a potential non-invasive tool in early detection of lung adenocarcinoma: a cross-sectional study.
Liu Q; Zhang W; Pei Y; Tao H; Ma J; Li R; Zhang F; Wang L; Shen L; Liu Y; Jia X; Hu Y
BMC Med; 2023 Oct; 21(1):409. PubMed ID: 37904139
[TBL] [Abstract][Full Text] [Related]
7. Whole Genome-Derived Tiled Peptide Arrays Detect Prediagnostic Autoantibody Signatures in Non-Small-Cell Lung Cancer.
Yan Y; Sun N; Wang H; Kobayashi M; Ladd JJ; Long JP; Lo KC; Patel J; Sullivan E; Albert T; Goodman GE; Do KA; Hanash SM
Cancer Res; 2019 Apr; 79(7):1549-1557. PubMed ID: 30723114
[TBL] [Abstract][Full Text] [Related]
8. Lipidomics reveals new lipid-based lung adenocarcinoma early diagnosis model.
Sun T; Chen J; Yang F; Zhang G; Chen J; Wang X; Zhang J
EMBO Mol Med; 2024 Apr; 16(4):854-869. PubMed ID: 38467839
[TBL] [Abstract][Full Text] [Related]
9. Extracellular vesicle long RNA markers of early-stage lung adenocarcinoma.
Zhang Y; Liu W; Zhang H; Sun B; Chen T; Hu M; Zhou H; Cao Y; Han B; Wu L
Int J Cancer; 2023 Apr; 152(7):1490-1500. PubMed ID: 36451312
[TBL] [Abstract][Full Text] [Related]
10. Plasma Exosomal CXCL7 is a Potential Biomarker for Lung Adenocarcinoma.
Fang W; You J; Xu Q; Jiang Y; Hu H; Chen F; Chen L
Clin Lab; 2022 Oct; 68(10):. PubMed ID: 36250818
[TBL] [Abstract][Full Text] [Related]
11. The diagnostic efficiency of seven autoantibodies in lung cancer.
Huang H; Luo W; Ni Y; Sun S; Wang C; Zhang L
Eur J Cancer Prev; 2020 Jul; 29(4):315-320. PubMed ID: 31764214
[TBL] [Abstract][Full Text] [Related]
12. Cancer Stemness-Based Prognostic Immune-Related Gene Signatures in Lung Adenocarcinoma and Lung Squamous Cell Carcinoma.
Li N; Li Y; Zheng P; Zhan X
Front Endocrinol (Lausanne); 2021; 12():755805. PubMed ID: 34745015
[TBL] [Abstract][Full Text] [Related]
13. Early detection of NSCLC with scFv selected against IgM autoantibody.
Pedchenko T; Mernaugh R; Parekh D; Li M; Massion PP
PLoS One; 2013; 8(4):e60934. PubMed ID: 23585862
[TBL] [Abstract][Full Text] [Related]
14. Identification of Immune-Related Gene Signatures in Lung Adenocarcinoma and Lung Squamous Cell Carcinoma.
Li N; Wang J; Zhan X
Front Immunol; 2021; 12():752643. PubMed ID: 34887858
[TBL] [Abstract][Full Text] [Related]
15. Development of somatic mutation signatures for risk stratification and prognosis in lung and colorectal adenocarcinomas.
Menor M; Zhu Y; Wang Y; Zhang J; Jiang B; Deng Y
BMC Med Genomics; 2019 Jan; 12(Suppl 1):24. PubMed ID: 30704450
[TBL] [Abstract][Full Text] [Related]
16. Construction and experimental validation of an acetylation-related gene signature to evaluate the recurrence and immunotherapeutic response in early-stage lung adenocarcinoma.
Wang H; Lu X; Chen J
BMC Med Genomics; 2022 Dec; 15(1):254. PubMed ID: 36503492
[TBL] [Abstract][Full Text] [Related]
17. Comparative Study of Autoantibody Responses between Lung Adenocarcinoma and Benign Pulmonary Nodules.
Wang J; Shivakumar S; Barker K; Tang Y; Wallstrom G; Park JG; Tsay JC; Pass HI; Rom WN; LaBaer J; Qiu J
J Thorac Oncol; 2016 Mar; 11(3):334-45. PubMed ID: 26896032
[TBL] [Abstract][Full Text] [Related]
18. [Early diagnosis of subtype in early clinical stage lung adenocarcinoma by using an autoantibody panel and computed tomography].
Meng QC; Gao PR; Ren PF; Song YP; Li HL
Zhonghua Yi Xue Za Zhi; 2019 Jan; 99(3):204-208. PubMed ID: 30669764
[No Abstract] [Full Text] [Related]
19. Comprehensive analysis of a novel signature incorporating lipid metabolism and immune-related genes for assessing prognosis and immune landscape in lung adenocarcinoma.
Wang Y; Xu J; Fang Y; Gu J; Zhao F; Tang Y; Xu R; Zhang B; Wu J; Fang Z; Li Y
Front Immunol; 2022; 13():950001. PubMed ID: 36091041
[TBL] [Abstract][Full Text] [Related]
20. Development of a multiplex autoantibody test for detection of lung cancer.
Jia J; Wang W; Meng W; Ding M; Ma S; Wang X
PLoS One; 2014; 9(4):e95444. PubMed ID: 24755629
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
